Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565812 · ClinicalTrials.gov registry record · Phase 2
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,457
- Enrollment target
NCT00565812 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,457 participants.
The verdict
NCT00565812, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,457 participants
- Enrollment target
Study Summary
The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.
Interventions
- DRUG Placebo
- DRUG SD-6010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,457 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00565812
The ClinicalTrials.gov registry entry for NCT00565812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00565812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00565812 about?
NCT00565812 is a clinical study titled "A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee". The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using join...
What is the current status of trial NCT00565812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,457 participants. The study started on 2007-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00565812?
The interventions under investigation include: Placebo (DRUG), SD-6010 (DRUG).
Who is sponsoring clinical trial NCT00565812?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.